CL2024002576A1 - Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados - Google Patents
Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionadosInfo
- Publication number
- CL2024002576A1 CL2024002576A1 CL2024002576A CL2024002576A CL2024002576A1 CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1 CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A CL2024002576 A CL 2024002576A CL 2024002576 A1 CL2024002576 A1 CL 2024002576A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- macro
- medium
- substituted heterocycle
- related uses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263315438P | 2022-03-01 | 2022-03-01 | |
| US202363439477P | 2023-01-17 | 2023-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002576A1 true CL2024002576A1 (es) | 2025-01-10 |
Family
ID=85772026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002576A CL2024002576A1 (es) | 2022-03-01 | 2024-08-29 | Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20250236629A1 (https=) |
| EP (1) | EP4486748A1 (https=) |
| JP (1) | JP2025507852A (https=) |
| KR (1) | KR20240157067A (https=) |
| CN (1) | CN119110802A (https=) |
| AU (1) | AU2023228830A1 (https=) |
| CA (1) | CA3245204A1 (https=) |
| CL (1) | CL2024002576A1 (https=) |
| IL (1) | IL315237A (https=) |
| MX (1) | MX2024010608A (https=) |
| TW (1) | TW202400606A (https=) |
| WO (1) | WO2023167925A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| KR20250155550A (ko) | 2023-03-16 | 2025-10-30 | 다케다 야쿠힌 고교 가부시키가이샤 | 매크로시클릭 헤테로시클 화합물 및 이의 용도 |
| US20240425521A1 (en) | 2023-06-01 | 2024-12-26 | H. Lundbeck A/S | Spiromacrocyclic orexin 2 receptor agonists |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US20200207734A1 (en) | 2017-08-03 | 2020-07-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| SG11202106791XA (en) | 2019-01-31 | 2021-07-29 | Takeda Pharmaceuticals Co | Heterocyclic compound and use thereof |
| FI4065585T3 (fi) * | 2019-11-25 | 2025-09-26 | Alkermes Inc | Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä |
| WO2022051583A1 (en) * | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
-
2023
- 2023-03-01 KR KR1020247032615A patent/KR20240157067A/ko active Pending
- 2023-03-01 IL IL315237A patent/IL315237A/en unknown
- 2023-03-01 WO PCT/US2023/014275 patent/WO2023167925A1/en not_active Ceased
- 2023-03-01 EP EP23713207.1A patent/EP4486748A1/en active Pending
- 2023-03-01 CN CN202380037293.8A patent/CN119110802A/zh active Pending
- 2023-03-01 TW TW112107384A patent/TW202400606A/zh unknown
- 2023-03-01 JP JP2024551975A patent/JP2025507852A/ja active Pending
- 2023-03-01 MX MX2024010608A patent/MX2024010608A/es unknown
- 2023-03-01 CA CA3245204A patent/CA3245204A1/en active Pending
- 2023-03-01 AU AU2023228830A patent/AU2023228830A1/en active Pending
-
2024
- 2024-08-28 US US18/817,943 patent/US20250236629A1/en active Pending
- 2024-08-29 CL CL2024002576A patent/CL2024002576A1/es unknown
-
2025
- 2025-04-11 US US19/177,396 patent/US20250289828A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN119110802A (zh) | 2024-12-10 |
| US20250289828A1 (en) | 2025-09-18 |
| TW202400606A (zh) | 2024-01-01 |
| US20250236629A1 (en) | 2025-07-24 |
| JP2025507852A (ja) | 2025-03-21 |
| IL315237A (en) | 2024-10-01 |
| EP4486748A1 (en) | 2025-01-08 |
| WO2023167925A1 (en) | 2023-09-07 |
| CA3245204A1 (en) | 2023-09-07 |
| MX2024010608A (es) | 2024-09-23 |
| AU2023228830A1 (en) | 2024-09-12 |
| KR20240157067A (ko) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024002576A1 (es) | Derivados heterocíclicos medio o macrocíclicos sustituidos con bencilo y usos relacionados | |
| WO2022051596A8 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| DOP2025000250A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| DOP2023000168A (es) | Compuestos antivirales que contienen nitrilo | |
| CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
| CO2022015930A2 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| CO2022012476A2 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| CL2022003041A1 (es) | Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 | |
| AR128931A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| UY39559A (es) | Compuestos y su uso | |
| CL2024003450A1 (es) | Compuestos y usos de estos | |
| UY30804A1 (es) | Derivados de nicotinamida, sus sales y solvatos, composiciones farmacéuticas conteniendolas y aplicaciones | |
| MX2019007071A (es) | Novedosos derivados del acido fenilpropionico y usos de los mismos. | |
| CL2021001396A1 (es) | Derivados de panteteína y usos de los mismos | |
| AR067538A1 (es) | Inhibidortes de la 11 beta -hidroxiesteroide-deshidrogenasa | |
| CO6400220A2 (es) | Derivados de sulfonamida | |
| CU24327B1 (es) | Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| CU20130116A7 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| MX2023013987A (es) | Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer. | |
| CL2025000285A1 (es) | Inhibidores de inflamasoma nlrp3 | |
| AR133953A1 (es) | Inhibidores del factor b del complemento y usos de los mismos | |
| MX2024003028A (es) | Derivados de 6 aza quinolina y usos relacionados. |